FDA Flags J&J For Inadequate Oversight Of Consumer Devices

FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, including K-Y moisturizers, after finding shortcomings in post-market monitoring and pre-market notification. The agency’s May 22 warning letter does not cite manufacturing issues.

FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, finding sufficient shortcomings in post-market monitoring and pre-market notification to warrant a warning letter.

J&J and subsidiary McNeil Consumer Healthcare say they have come a long way in improving management of OTC pharma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Post-Marketing Regulation & Studies

More from Product Reviews